UNITED THERAPEUTICS Corp

Form 4 July 02, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Estimated average

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person

2. Issuer Name and Ticker or Trading

DWEK RAYMOND

Symbol

LINITED THER APELITICS Cor

(Zip)

5. Relationship of Reporting Person(s) to

Issuer

UNITED THERAPEUTICS Corp [UTHR]

(Check all applicable)

(Last) (First) (Middle) 3. Dat

3. Date of Earliest Transaction (Month/Day/Year) 07/02/2015

X Director _____ 10% Owner ____ Officer (give title _____ Other (specify

C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET

(Street)

(State)

4. If Amendment, Date Original Filed(Month/Day/Year)

 ${\bf 6.\ Individual\ or\ Joint/Group\ Filing} (Check$

Applicable Line)

X Form filed by One Reporting Person ____ Form filed by More than One Reporting

SILVER SPRING, MD 20910

(City)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

•		1 an	16 1 - 14011-1	Derivativ	Secu	nines Acquir	cu, Disposeu oi, e	or Denemerally	Owneu
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(A) or		Transaction(s)	(Instr. 4)		
			Code V	Amount		Price	(Instr. 3 and 4)		
Common Stock	07/02/2015		M(1)	3,000	A	\$ 31.17 (2)	3,000	D	
Common Stock	07/02/2015		S(1)	1,010	D	\$ 174.13 (3)	1,990	D	
Common Stock	07/02/2015		S <u>(1)</u>	100	D	\$ 172.53	1,890	D	
Common Stock	07/02/2015		S(1)	1,890	D	\$ 170.1755 (4)	0	D	

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2.		3. Transaction Date	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and Amount of	
Derivative Conversi		(Month/Day/Year)	Execution Date, if	Transaction of Derivative		Expiration Date		Underlying Securities	
Security	or Exercise		any	Code Securities		(Month/Day/Year)		(Instr. 3 and 4)	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8) Acquired					
	Derivative			(A) or					
	Security			Disposed of					
				(D)					
					(Instr. 3, 4,				
					and 5)				
									Amount
									or
						Date	Expiration	Title	Number
						Exercisable	Date	1100	of
				Code V	(A) (D)				Shares
				Code v	(11) (D)				Silares
Stock	\$ 31.17	07/02/2015		N 4 (1)	2.000	06/06/0000	06/06/0017	Common	2.000
Options	(2)	07/02/2015		M <u>(1)</u>	3,000	06/26/2008	06/26/2017	Stock	3,000

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

DWEK RAYMOND C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING, MD 20910



Signatures

/s/ John S. Hess, Jr. under Power of Attorney 07/02/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- (2) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
 - This transaction was executed in multiple trades at prices ranging from \$173.57 to \$174.345. The price reported above reflects the
- (3) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reporting Owners 2

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

This transaction was executed in multiple trades at prices ranging from \$170.00 to \$170.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.